Dexcom has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up. John Lister, Dexcom’s General Manager for EMEA, says, “The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for fingersticks, but it also maintains the performance, connectivity and accuracy that the diabetes community has come to expect from Dexcom CGM. The groundbreaking Dexcom G6 will be available in the U.K. and Ireland this month. Dexcom G6 encompasses new features that empower users to take control of their diabetes.”
As per our Kit That’s Coming Soon news item that appeared on Monday 11 June, the new G6 has several improvements and new features over the previous generations of the technology, including eliminating the need for a blood test to calibrate and 10-day sensor wear. Read more HERE.
Doctor Nick Oliver from Imperial College London, says of the new sensor, “For many years, fingerstick blood glucose testing has been a critical component of diabetes self-management. However, the self-monitoring, which can sometimes mean testing blood up to ten or more times a day, can be time-consuming, painful and difficult to fit into a busy day. The Dexcom G6 presents a major advancement for the continuous glucose monitoring category. With Dexcom G6, people with diabetes now have the freedom to live without routine fingersticks and can rely on their CGM data to make treatment decisions, enabling more personalised and effective self-management.”
Available for orders now for delivery by the end of June, Dexcom G6 is 28% cheaper than the previous G5 model. The system includes a new G6 transmitter and sensors. The new touch screen receiver is optional for international users and can be purchased separately. Users will need a touch screen receiver or compatible smart device and the G6 app, along with the new G6 sensors and transmitter.
For more on pricing, see THIS LINK.
The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC. The powerful and ground-breaking new system is also the first CGM system to receive the US Food and Drug Administration’s (FDA) De Novo classification. With this new classification, the Dexcom G6 CGM system is indicated for use as both a stand-alone CGM and for integration into automated insulin dosing (AID) systems. For more information on Dexcom G6, visit www.dexcom.com/en-GB
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it’s free, and you can easily unsubscribe should you wish to).
